Core Insights - The event "Hand in Hand with Hong Kong, Discussing the Future" was successfully held in Hong Kong, organized by Shuangyi Pharmaceutical and RaffAello, focusing on corporate development, industry trends, and investment opportunities [1][3] - Chairman Wang Bo emphasized that 2026 is a critical year for Shuangyi Pharmaceutical's transformation and high-quality development, aiming to leverage Hong Kong's international financial advantages to showcase Guangxi's achievements and promote key products globally [3][5] Company Strategy - Shuangyi Pharmaceutical is committed to implementing a "dual brand" strategy, aiming to establish its flagship product, Shuangyi Qushi Tongluo Capsule, as a global leader while also striving to make its compound cold medicine granules a market champion [5] - The company plans to expand its business both domestically and internationally, focusing on product-centric and market-oriented approaches, with a vision to enhance collaboration with partners for broader development opportunities [5] Industry Reception - Attending fund managers praised Shuangyi Pharmaceutical's dedication to ethnic Zhuang medicine and its commitment to independent innovation, recognizing the company's growth journey as a testament to resilience and potential [5] - The overall atmosphere of the event was positive, with deep exchanges and interactions, reflecting the company's commitment to its corporate spirit of unity, diligence, perseverance, and innovation [6]
双蚁药业联袂RaffAello及多家基金机构齐聚香江 擘画国际化发展新蓝图
Jiang Nan Shi Bao·2026-02-17 05:10